Saniona finishes six months double blind Phase 2a trial of Tesomet
Category: #health  | By Mateen Dalal  | Date: 2020-03-20 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Saniona finishes six months double blind Phase 2a trial of Tesomet

Saniona, a renowned biopharmaceutical firm focusing on rare disorders of the central nervous system, has reportedly announced that the last patient has successfully completed the last visit in the company’s six-month, double blind Phase 2a study of Tesomet in HO (Hypothalamic Obesity).

A total of 18 patients, from the initial 21 who had started the trial, have now resumed the open-label extension part of the study. The placebo-measured part of the study remains on track to report top-line results in the second quarter of 2020.

Rami Levin, CEO, Saniona, stated that the company is thrilled that the Phase 2a trial of Tesomet is beginning as per the plan, at a time of such ambiguity and disruption across the globe caused by the COVID-19 virus.

Levin further stated that the study is an essential part of the clinical package which Saniona is accumulating, as the company is quickly advancing Tesomet for pivotal clinical trials in the rare eating disorder of HO as part of its long-term strategy of becoming a globally recognized commercial stage biopharma company.

The Phase 2a study is a double-blind, randomized, placebo-controlled, exploratory Phase 2a trial in patients with disorder of HO, led at  Rigshospitalet in Copenhagen, Denmark. Under the trial, patients have received either matching placebo or Tesomet for 24 weeks. This is followed by an open-label expansion study where all patients would get Tesomet for 24 weeks bringing about a complete treatment period of 48 weeks. Saniona hopes to report the outcomes from the double-blind part of the study in the second quarter of 2020.

The key endpoint is total tolerability and safety, which would be determined after considering all the safety data collected during the study, which includes laboratory data, recorded adverse events, heart rate, and blood pressure. The secondary endpoints are related to body composition; appetite & satiety; quality of life; bodyweight; craving for salty, sweet, and fatty foods; and metabolic parameters & lipids.

Source credit: https://www.bioportfolio.com/news/article/4253602/Saniona-completes-its-six-months-double-blind-Phase-2a-trial-of-Tesomet.html

 

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Apollo plans to expand looking at average occupancy surge

Apollo plans to expand looking at average occupancy surge

By Mateen Dalal

Apollo Hospitals Enterprises Ltd., one of India's leading healthcare providers, is reportedly targeting to increase the average occupancy rate in its hospitals to 68-70% for the fiscal year 2024. The company recently announced impressive finan...

ChatGPT’s creator OpenAI proposes regulation of AI by humans

ChatGPT’s creator OpenAI proposes regulation of AI by humans

By Mateen Dalal

OpenAI, the creator of ChatGPT, has reportedly put forward a proposal for the establishment of an international organization to regulate artificial intelligence (AI). Led by CEO Sam Altman, the company believes that AI systems developed within the ne...

Medtronic pledges USD 350 Mn to expand R&D operations in India

Medtronic pledges USD 350 Mn to expand R&D operations in India

By Mateen Dalal

Medtronic, a leading healthcare technology company, has announced plans to expand its R&D center in Hyderabad, India, with a whopping investment of USD 350 million. The existing facility is already the largest center for the company outside the U...